Jacob Bell is a Senior Reporter at BioPharma Dive. He specializes in covering themes related to medicine and healthcare, pharmaceuticals, and sports, with a focus on topics such as pharmaceutical manufacturing, regulation, and competitive sports. Jacob's work has been featured in notable publications including BioPharma Dive, PharmaVoice, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jacob Bell's coverage is heavily focused on the healthcare and pharmaceutical industries, with particular attention to biotechnology. His articles often incorporate press releases and data citations, indicating a preference for factual and industry-specific information.
Given his focus on private sector announcements, Jacob may be interested in pitches related to new product launches, significant investments or acquisitions within the healthcare and biotech sectors. Furthermore, he might be open to expert commentary from professionals well-versed in various aspects of biotechnology, pharmaceuticals, neurological diseases such as ALS research or gene therapy.
As there is no specific geographic focus mentioned for Jacob's coverage area, it would be beneficial to provide globally relevant insights pertaining to the topics covered.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Former Commodore inks two-way contract
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
Gallatin native becomes second Vanderbilt women’s golfer to earn top academic billing
Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
By: Jacob Bell
The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
By: Jacob Bell
To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
By: Jacob Bell
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
